THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018

Mamoura Diversified Global Holding PJSC ("MDGH") - Investment into PCI Pharma Services

On 11 July 2025, a wholly-owned subsidiary of MDGH entered into an agreement to reinvest into PCI Pharma Services, a world-leading global contract development and manufacturing organization focused on innovative biotherapies. The completion of the transaction is subject to customary closing conditions and regulatory approvals.

For further information, please contact:

Mamoura Diversified Global Holding PJSC

P.O. Box 45005, Abu Dhabi, United Arab Emirates

Telephone:     +971 2 413 0000

Fax:                +971 2 413 0001

Email:              ir@mubadala.ae (for investor relations queries)

media@mubadala.ae (for media queries)

This announcement is released by MDGH GMTN (RSC) Ltd and contains information that qualified or may have qualified as inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (UK MAR), encompassing information relating to the Global Medium Term Note Programme established by MDGH GMTN (RSC) Ltd. For the purposes of UK MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, this announcement is made by the directors of MDGH GMTN (RSC) Ltd.